Shahnaz Khan

Mrs. Shahnaz Khan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
MBMeryem Bektas
Meryem Bektas
TBTimothy Bell
Timothy Bell
SKShahnaz Khan
Shahnaz Khan
BTBrad Tumminello
Brad Tumminello
MFMaria M. Fernandez
Maria M. Fernandez
AOAna B. Oton
Ana B. Oton
Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are characterized by infiltrative growth and can affect organs and adjacent structures, resulting in substantial clinical burden impacting patients’ health-related quality of life. Searches of PubMed, Embase, Cochrane, and key conferences were conducted in November 2021 and updated periodically through March 2023 to identify articles describing the burden of DT. Of 651 publications identified, 96 relevant ones were retained. Diagnosis of DT is challenging because of its morphologic heterogeneity and variable clinical presentation. Patients visit multiple healthcare providers, often facing delays in correct diagnosis. The low incidence of DT (estimated 3–5 cases per million person-years) limits disease awareness. Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases). Frequently mentioned symptoms are pain, limited function and mobility, fatigue, muscle weakness, and swelling around the tumor. Overall, quality of life in patients with DT is lower than in healthy controls. There is no treatment approved by the US Food and Drug Administration for DT; however, treatment guidelines reference available options, such as active surveillance, surgery, systemic therapy, and locoregional therapy. Choice of active treatment may depend on tumor location, symptoms, and risk of morbidity. The substantial burden of illness of DT is related to difficulties in timely and accurate diagnosis, high symptom burden (pain and functional limitations), and decreased quality of life. There is a high unmet need for treatments that specifically target DT and improve quality of life.

14 November 2018 in World Journal of Gastroenterology
Verified
Journal Article
Open access
JPJulian Panes
Julian Panes
WRWalter Reinisch
Walter Reinisch
EREwa Rupniewska
Ewa Rupniewska
SKShahnaz Khan
Shahnaz Khan
JFJoan Forns
Joan Forns
HPHaridarshan Patel
Haridarshan Patel
Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review

14 March 2019 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
SKShahnaz Khan
Shahnaz Khan
EREwa Rupniewska
Ewa Rupniewska
MNMackenzie Neighbors
Mackenzie Neighbors
DSDavid Singer
David Singer
JCJoseph Chiarappa
Joseph Chiarappa
COCamilo Obando
Camilo Obando
What is known and objective The application of biologics to treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is well established. Our aim was to characterize the most recent five years of data on rates of adherence, persistence, switching and dose escalations with biologics used to treat IBD in the United States. Methods We systematically reviewed electronic databases MEDLINE, MEDLINE In‐Process, EMBASE and Cochrane Library for 2012‐2017 as well as conference proceedings for 2016‐2017 published in English. Results and discussion Of 449 records identified, 41 met all screening criteria. Published studies varied greatly in methodology, data sources, population studied, follow‐up time and endpoint definitions, preventing meaningful comparisons across studies. Based on studies using a medication possession rate threshold of <80% or <86%, 38%‐77% of patients were found non‐adherent to biologics. Discontinuation within the first 3 months occurred in 0%‐25% of patients in six studies; 7%‐65% discontinued by 12 months in 13 studies. Among all patients who initiated an index biologic, the switch rate to another biologic ranged from 4.5% to 20% in 6 studies. Dose escalations were reported in only four studies; 8%‐35% of patients had their dose escalated within the first year of therapy. What is new and conclusion This study demonstrates variability in study design and methodology to assess adherence, persistence, switching and dose escalation with biologics among adults with IBD in the United States. Our findings suggest that real‐world biologic use may be suboptimal and indicate new therapies and/or additional patient support may be needed.

1 May 2023 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
SBSophie J Bakri
Sophie J Bakri
MBMeryem Bektas
Meryem Bektas
DSDarcie Sharp
Darcie Sharp
RLRoger Luo
Roger Luo
SSSujata P Sarda
Sujata P Sarda
SKShahnaz Khan
Shahnaz Khan
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the m...

1 December 2020 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
MBMeryem Bektas
Meryem Bektas
CCCatherine Copley-Merriman
Catherine Copley-Merriman
SKShahnaz Khan
Shahnaz Khan
SSSujata P Sarda
Sujata P Sarda
JSJamile M Shammo
Jamile M Shammo
The complement system is part of the innate immune response system, which comprises more than 50 distinct plasma and serum proteins that interact to opsonize pathogens (i.e., mark pathogens for des...

24 December 2024 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
EHEmily K. Horn
Emily K. Horn
ELElizabeth M. La
Elizabeth M. La
MBMeryem Bektas
Meryem Bektas
SKShahnaz Khan
Shahnaz Khan
SGSusan I. Gerber
Susan I. Gerber
Respiratory syncytial virus (RSV) vaccination could improve health equity by protecting individuals who are disproportionally at increased risk of RSV infection and severe RSV-related outcomes. However, limited information is available about RSV-related disparities among United States (US) adults. We reviewed US-specific literature regarding disparities across adult populations in having risk factors for severe RSV disease (cardiopulmonary disease, diabetes, liver disease, kidney disease). We summarize available evidence regarding disparities in having or being diagnosed with RSV, as well as experiencing severe RSV-related health outcomes. Disparities are analyzed by race, ethnicity, socioeconomic status, and other social determinants of health. RSV-related disparities are observed across all outcomes of interest, although RSV-specific data are limited in some cases. Racial and ethnic minority groups and socioeconomically disadvantaged populations are more likely to have risk factors for severe RSV disease, overall and at younger ages, yet individuals from these groups are more often underdiagnosed. Disparities in RSV-related hospitalizations, emergency department visits, and deaths are observed, especially among adults from racial and ethnic minority groups, of lower socioeconomic status, and in poorer or more crowded neighborhoods. Findings highlight the importance of RSV vaccination among these groups to improve health equity.